Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.

Katharina SeystahlBettina HentschelSarah LoewDorothee GramatzkiJörg FelsbergUlrich HerrlingerManfred WestphalGabriele SchackertNiklas ThonMarcos TatagibaTorsten PietschGuido ReifenbergerMarkus LöfflerWolfgang WickMichael Wellernull null

Published in: Journal of cancer research and clinical oncology (2019)

This study confirms limited value of bevacizumab in recurrent glioblastoma independent of MGMT status. Alkylating agents have activity in recurrent glioblastoma, especially in the context of MGMT promoter methylation.

Keyphrases

dna methylation
transcription factor
genome wide
radiation therapy